Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084879 | 0.91 | PTGS2 (0.46) | PTGS2PTGS1 | |
| SCHEMBL2084273 | 0.91 | PTGS2 (0.46) | PTGS2PTGS1 | |
| SCHEMBL1573242 | 0.91 | PTGS2 (0.50) | PTGS2PTGS1 | |
| SCHEMBL1573094 | 0.90 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL2086108 | 0.89 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL2086039 | 0.89 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL27750165 | 0.88 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL2084431 | 0.86 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL3397783 | 0.85 | PTGS2 (0.40) | PTGS2PTGS1 | |
| SCHEMBL1573206 | 0.83 | PTGS2 (0.53) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542978-B1 | NOVEL BIO-ACTIVE MOLECULES | ORCHID RES LAB LTD (IN) | 2011-04-13 | — | — | EP | claimed |
| US-7317014-B2 | Bio-active pyrimidine molecules | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2008-01-08 | — | — | US | claimed |
| EP-1542978-A1 | NOVEL BIO-ACTIVE MOLECULES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2005-06-22 | — | — | EP | claimed |
| US-20050107413-A1 | Novel bio-active molecules | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2005-05-19 | — | — | US | claimed |
| WO-2004009560-A1 | NOVEL BIO-ACTIVE MOLECULES | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2004-01-29 | — | — | WO | claimed |
| EP-1973884-B1 | NOVEL HETEROCYCLES | ORCHID PHARMA LTD (IN) | 2016-08-03 | — | — | EP | disclosed |
| CN-101965338-B | Heterocyclic rings | ORCHID RES LAB LTD | 2014-09-17 | — | — | CN | disclosed |
| US-8828999-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2014-09-09 | — | — | US | disclosed |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (IN) | 2013-07-04 | — | — | US | disclosed |
| US-8420653-B2 | Pyrimidine compounds and their uses | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-04-16 | — | — | US | disclosed |
| EP-1542978-B1 | NOVEL BIO-ACTIVE MOLECULES | ORCHID RES LAB LTD (IN) | 2011-04-13 | — | — | EP | disclosed |
| CN-101965338-A | Novel heterocycles | ORCHID RES LAB LTD | 2011-02-02 | — | — | CN | disclosed |
| EP-1973884-A2 | NOVEL HETEROCYCLES | Orchid Research Laboratories Limited (IN) | 2008-10-01 | — | — | EP | disclosed |
| US-20080207606-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2008-08-28 | — | — | US | disclosed |
| US-7317014-B2 | Bio-active pyrimidine molecules | ORCHID RESEARCH LABORATORIES, LTD. (IN) | 2008-01-08 | — | — | US | disclosed |
| WO-2007083182-A2 | NOVEL HETEROCYCLES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167413-A1 | Novel heterocycles | ORCHID RESEARCH LABORATORIES LIMITED. (IN) | 2007-07-19 | — | — | US | disclosed |
| EP-1542978-A1 | NOVEL BIO-ACTIVE MOLECULES | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2005-06-22 | — | — | EP | disclosed |
| US-20050107413-A1 | Novel bio-active molecules | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
| WO-2004009560-A1 | NOVEL BIO-ACTIVE MOLECULES | ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207606-A1 | Novel heterocycles | GPR4, UACA, PDE4A | PTGS2 1346/4885PTGS1 622/4885 |
| US-20050107413-A1 | Novel bio-active molecules | ABCG2, UGT2B7, UGT1A1 | PTGS2 2960/4885PTGS1 2622/4885 |
| US-20070167413-A1 | Novel heterocycles | MCL1, UACA, MYLK2 | PTGS2 1550/4885PTGS1 809/4885 |
| US-20130172350-A1 | PYRIMIDINE COMPOUNDS AND THEIR USES | UMPS, PNP, PDE4A | PTGS2 1485/4885PTGS1 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.